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Botswana’s national HIV/
AIDS treatment programme: 
2002 - 2010
Farahani et al. analysed the effect of the 
implementation of Botswana’s national antiretroviral 
treatment programme (Masa (‘new dawn’)), which was started in 
January 2002, up to 2010. It is known that short-term mortality 
among HIV patients receiving antiretroviral therapy in sub-
Saharan Africa is higher than that recorded in high-income 
countries. So far, no systematic long-term comparisons have been 
made because of the scarcity of available data. 
Data for patients who were eligible for antiretroviral therapy, 
according to Botswana’s national guidelines, were collected 
prospectively through a clinical information system developed 
by the Botswana Ministry of Health. A dataset of all available 
electronic records for adults patients (>18 years old) who had 
enrolled by 30 April 2010 was anonymised, extracted and used for 
analysis by the study team. The primary outcome was mortality. 
Loss to follow-up was established using a sensitivity analysis, 
which assumed that varying proportions of the population lost to 
follow-up had died
The study team analysed the records of 126  263 patients, of 
whom 102 713 had documented initiation of antiretroviral therapy. 
The median follow-up time was 35 months, with a median of 8 
follow-up visits. More than half (63%) of the study population were 
women, with a median age at baseline of 34 years. The median age 
for men was 38 years. During the 9 years of the study 10 230 deaths 
were recorded and mortality was highest during the first 3 months 
after treatment had started, but this decreased in the second year 
of treatment, decreasing still further during the next 7 years of 
follow-up. 
In each calendar year after the start of the Masa programme, 
average CD4+ cell counts at enrolment increased (from 101 cells/μl 
in 2002 to 191 cells/μl in 2010). In each year, the proportion of the 
total enrolled population who died in that year decreased, from 
63% (88 of 140) in 2002 to 0.8% (13 of 1 599) in 2010. A sensitivity 
analysis, assuming that 60% of the population lost to follow-up had 
died, showed 3 000 additional deaths, increasing overall mortality 
from 8% to 11 - 13%.
The conclusion was that the Botswana national HIV/AIDS 
treatment programme reduced mortality among adults with HIV 
to levels that were similar to those of other low-income or middle-
income countries.
Farahani M, Vable A, Lebelonyane R, et al. Outcomes of the Botswana national HIV/AIDS treatment 
programme from 2002 to 2010: A longitudinal analysis. Lancet Global Health 2014;2(1):e44-e50. [http://
dx.doi.org/10.1016/S2214-109X(13)70149-9]
Diuretics, beta-blockers and 
statins and new-onset type 2 
diabetes
Beta-blockers, diuretics and statins are established 
drugs in the management of cardiovascular disease 
and there is general consensus that statins reduce risk factors for 
coronary artery disease. However, there continues to be debate about 
their role in primary prevention in lower-risk populations. One 
of the main areas of controversy is the association of statins with 
new-onset type 2 diabetes. Shen et al., writing in the British Medical 
Journal, examined the degree to which using beta-blockers, statins 
and diuretics in patients with impaired glucose tolerance and other 
cardiovascular risk factors is associated with new-onset diabetes.
Their study focused on a re-analysis of data from the Nateglinide 
and Valsartan in Impaired Glucose Tolerance Outcome Research 
(NAVIGATOR) trial. This trial enrolled patients who, at baseline, were 
treatment naïve to beta-blockers, diuretics, statins and calcium channel 
blockers, the latter being used as metabolically neutral controls.
Their main outcome measure was the development of new-onset 
diabetes diagnosed using standard plasma glucose levels in all 
participants, which was confirmed with glucose tolerance testing 
within 12 weeks.
During five years of follow-up, beta-blockers were prescribed to 
915 patients, diuretics to 1 316, statins to 1 353 and calcium channel 
blockers to 1 171. After adjusting for confounders, the analysis found 
that both diuretics and statins were associated with an increased 
risk of new-onset diabetes, but beta-blockers and calcium channel 
blockers were not.
This study adds to the body of evidence that suggests that in high-
risk patients with impaired glucose tolerance the use of diuretics and 
statins may be associated with an increased risk of new-onset diabetes. 
Shen L, Shah BR, Reyes EM, et al. Role of diuretics, β blockers, and statins in increasing the risk of diabetes 
in patients with impaired glucose tolerance: Reanalysis of data from the NAVIGATOR study. Br Med J 
2013;347:f6745. [http://dx.doi.org/10.1136/bmj.f6745]
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